Franzone J S, Reboani M C, Mason U, Villani F
Research Laboratories, Istituto Biologico Chemioterapico, ABC, S.p.A., Turin, Italy.
Arzneimittelforschung. 1990 Sep;40(9):987-93.
Iron lysozyme glutarate (ABC 1020) is a new soluble complex with an anti-anaemic activity superior to that of ferritin, ferrous sulphate and iron succinyl protein. Iron serum concentrations after treatment with ABC 1020 are higher than after ferritin and iron succinyl protein and lower than after ferrous sulphate treatment. Anaemic adult rats and rats born from dams with anaemia induced by an iron-deficient diet and by repeated bleeding showed considerable, dose-related improvement when treated with ABC 1020, which gave markedly better results than ferritin, iron succinyl protein and ferrous sulphate. Treatment with all four compounds improved the hematological and blood chemistry parameters considered, and reversed cardio- and splenomegaly. Preliminary data show that ABC 1020 is well tolerated, does not induce gastric lesions and has a high bioavailability.
戊二酸铁溶菌酶(ABC 1020)是一种新型可溶性复合物,其抗贫血活性优于铁蛋白、硫酸亚铁和琥珀酰铁蛋白。用ABC 1020治疗后的血清铁浓度高于铁蛋白和琥珀酰铁蛋白治疗后,低于硫酸亚铁治疗后。贫血成年大鼠以及由缺铁饮食和反复出血诱导贫血的母鼠所生的大鼠,用ABC 1020治疗后显示出显著的、剂量相关的改善,其效果明显优于铁蛋白、琥珀酰铁蛋白和硫酸亚铁。用这四种化合物治疗均改善了所考虑的血液学和血液化学参数,并逆转了心脏和脾脏肿大。初步数据表明,ABC 1020耐受性良好,不会诱发胃部病变,且具有高生物利用度。